Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients

Running, not enrolling

Conditions studied: Glioblastoma Multiforme

In brief

To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness

Key facts

Study ID
NCT06054529
Run by
AdventHealth Translational Research Institute
People needed
2
Starts
2023-09-11
Expected to finish
2025-12-01
Last updated by the study team
2025-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.